



BioMarker  
STRATEGIES

## **News Release**

---

**Contact:**

**Jerry Parrott, President & CEO**

**301-938-4043 Mobile**

**[jparrott@biomarkerstrategies.com](mailto:jparrott@biomarkerstrategies.com)**

FOR IMMEDIATE RELEASE

June 4, 2018

### **BioMarker Strategies Announces Chinese Patent for PathMAP Functional Signaling Profile Technology**

*“Compositions and Methods for Prediction of Drug Sensitivity, Resistance, and Disease Progression” (Chinese Patent #ZL 201180030332.9) - Exclusivity until April 2031*

Rockville, MD – June 4, 2018 – BioMarker Strategies, LLC, today announced that the Chinese Patent Office has granted a patent covering the Company’s PathMAP® Functional Signaling Profile technology. The announcement was made today at the BIO International Convention, which is back in Boston, Massachusetts to celebrate history-making innovation.

“PathMAP Functional Signaling Profiles are made possible by our proprietary SnapPath Cancer Diagnostics System, which was developed specifically to enable predictive tests to guide targeted drug development and treatment selection for patients with solid tumor cancers,” said Jerry Parrott, President and CEO, BioMarker Strategies. “PathMAP Profiles are highly predictive of individual solid tumor responses to targeted therapies and combinations because they are based on the dynamic, predictive signaling information available only from live cells.”

The SnapPath and PathMAP technologies are ideally suited to assess response to targeted drugs in development for treatment of solid tumor cancers. The BioMarker Strategies business model is focused on using its proprietary *ex vivo* technology to provide research services to companies developing targeted drugs and combinations for the treatment of patients with these cancers.

“Our Company was founded to address the reality that available biomarker tests for solid tumors primarily rely on dead, fixed tissue samples,” Mr. Parrott said. “Tests based on such static samples can identify mutations and suggest general therapeutic approach, but are not generally useful in identifying or understanding mechanisms of acquired resistance, and do not accurately and dependably predict individual tumor response to treatment.”

NEWS RELEASE

**Patents Granted BioMarker Strategies for the SnapPath® Cancer Diagnostics System:  
“Improved Methods and Devices for Cellular Analysis”**

<u>Country/Region</u>	<u>Patent #</u>	<u>Issue Date</u>	<u>Expiration</u>
United States	US9121801	September 1, 2015	December 28, 2030
Europe	EP2210080	January 28, 2015	October 24, 2028
Australia	AU2008317329	January 15, 2015	October 24, 2028
Australia	AU2014277688	January 19, 2017	October 24, 2028
Canada	CA2703631	August 22, 2017	October 24, 2028
Hong Kong	HK1145878	August 14, 2015	October 24, 2028
Japan	JP6177841	July 21, 2017	October 24, 2028
Korea	KR10-1658245	September 9, 2016	October 24, 2028

**Patents Granted for the Company’s PathMAP® Functional Signaling Profile Technology:  
“Compositions for Prediction of Drug Sensitivity, Resistance and Disease Progression”**

<u>Country/Region</u>	<u>Patent #</u>	<u>Issue Date</u>	<u>Expiration</u>
United States	US9766249	September 19, 2017	August 31, 2025
Europe	EP2561368	August 2, 2017	April 18, 2031
Australia	AU2011242990	May 28, 2015	April 18, 2031
Canada	CA2795362	March 20, 2018	April 18, 2031
China	ZL201180030332.9	April 13, 2018	April 18, 2031
Japan	JP6158078	June 16, 2017	April 18, 2031
Singapore	SG184507	May 6, 2015	April 18, 2031

**About BioMarker Strategies**

BioMarker Strategies developed the SnapPath Cancer Diagnostics System. SnapPath is an automated and highly customizable fluidics-based system consisting of a compact bench-top instrument and a single-use cartridge for required consumables and reagents. The SnapPath System generates purified populations of live solid tumor cells from fresh biopsies or other fresh tissue samples such as xenografts or tumorgrafts, and keeps them alive on the instrument to enable generation of the highly predictive PathMAP Functional Signaling Profiles.

The capabilities of SnapPath and the Functional Signaling Profiles it enables are available for use in preclinical studies in tumorgraft and other model systems, and in early clinical studies to assess pharmacodynamic changes in the solid tumors of individual patients. For more information about BioMarker Strategies, please see [www.biomarkerstrategies.com](http://www.biomarkerstrategies.com).

**Forward-Looking Statements**

The information in this press release includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here.

###